Back to results
US 2011/0300133 A1Published application
Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
AssigneeAbbott Biotherapeutics Corp.
InventorsVanitha RAMAKRISHNAN, David Powers, Dale E. Johnson, Ursula Jeffry, Vinay Bhaskar
Life of this patent
Estimating the term…
Abstract
The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
Claims9
A chimeric or humanized anti-α5β1 integrin antibody comprising:
- a heavy chain comprising a variable region amino acid sequence comprising all of the complementary determining regions (CDRs) from SEQ ID NO:1;
- a light chain comprising a variable region amino acid sequence comprising all of the complementary determining regions (CDRs) from SEQ ID NO:7;
- and
- a constant region, wherein the source of the constant region is a human IgG.
1 more element
Dependencies are inferred from the claim text.